Literature DB >> 28224303

Conjunctival cytologic features in patients with unilateral primary acquired nasolacrimal duct obstruction.

Nilay Yuksel1,2, Melek Mutlu3, Aydan Kilicarslan4, Emine Akcay3.   

Abstract

PURPOSE: To evaluate the cytologic features of conjunctival epithelium in patients with unilateral primary acquired nasolacrimal duct obstruction (PANDO) using impression cytology.
METHODS: Twenty-four patients with unilateral PANDO for at least 1 year were enrolled in this study. The healthy eyes of the patients are assessed as control group. All patients were subjected to ophthalmic surface examination with conjunctival impression cytology analysis. Squamous metaplasia and goblet cell density were graded according to Nelson grading system.
RESULTS: The mean age was 52.7 ± 16.3 (range 21-70) years. The mean period for complaints of epiphora was 3.2 ± 2.4 (range 1-8) years. The eye with PANDO had a mean squamous metaplasia grade of 2.38 ± 0.59 versus 1.91 ± 0.82 for control eyes (p = 0.011). The mean grade of goblet cell density was 2.0 ± 0.51 for eyes with PANDO and 2.38 ± 0.65 for control eyes (p = 0.013). There was no statistically significant correlation between conjunctival cytological features in terms of squamous metaplasia and goblet cell density grades and duration of epiphora complaint (r = -0.04, p = 0.82; r = 0.09, p = 0.66, respectively).
CONCLUSIONS: PANDO may cause alterations in conjunctival impression cytology. Successful dacryocystorhinostomy surgeries will help to protect ocular surface health.

Entities:  

Keywords:  Conjunctival impression cytology; Epiphora; Nasolacrimal duct obstruction

Mesh:

Year:  2017        PMID: 28224303     DOI: 10.1007/s10792-017-0471-0

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  18 in total

1.  Assessment of size and nucleo-cytoplasmic characteristics of the squamous cells of the corneal epithelium.

Authors:  Michael J Doughty
Journal:  Clin Exp Optom       Date:  2015-02-12       Impact factor: 2.742

Review 2.  Conjunctival epithelial and goblet cell function in chronic inflammation and ocular allergic inflammation.

Authors:  Darlene A Dartt; Sharmila Masli
Journal:  Curr Opin Allergy Clin Immunol       Date:  2014-10

3.  Tear-Film Osmolarity Changes Following Dacryocystorhinostomy in Primary Acquired Nasolacrimal Duct Obstruction.

Authors:  Nilay Yuksel; Emine Akcay; Berna Ayan; Necati Duru
Journal:  Curr Eye Res       Date:  2016-07-15       Impact factor: 2.424

4.  Staging of conjunctival squamous metaplasia by impression cytology.

Authors:  S C Tseng
Journal:  Ophthalmology       Date:  1985-06       Impact factor: 12.079

5.  Mild and moderate asthma is associated with airway goblet cell hyperplasia and abnormalities in mucin gene expression.

Authors:  C L Ordoñez; R Khashayar; H H Wong; R Ferrando; R Wu; D M Hyde; J A Hotchkiss; Y Zhang; A Novikov; G Dolganov; J V Fahy
Journal:  Am J Respir Crit Care Med       Date:  2001-02       Impact factor: 21.405

6.  Association of IL-21 cytokine with severity of primary Sjögren syndrome dry eye.

Authors:  Sung A Lim; Doo Hyun Nam; Jee Hye Lee; Seung-Ki Kwok; Sung-Hwan Park; So-Hyang Chung
Journal:  Cornea       Date:  2015-03       Impact factor: 2.651

Review 7.  Intestinal goblet cells and mucins in health and disease: recent insights and progress.

Authors:  Young S Kim; Samuel B Ho
Journal:  Curr Gastroenterol Rep       Date:  2010-10

8.  Changes in cytokines in tears after endoscopic endonasal dacryocystorhinostomy for primary acquired nasolacrimal duct obstruction.

Authors:  J K Lee; T H Kim
Journal:  Eye (Lond)       Date:  2014-02-28       Impact factor: 3.775

9.  Impression cytology.

Authors:  J D Nelson
Journal:  Cornea       Date:  1988       Impact factor: 2.651

10.  Morphological changes in ocular surface in dry eyes and other disorders by impression cytology.

Authors:  L Rivas; M A Oroza; A Perez-Esteban; J Murube-del-Castillo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.